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Editorial
Whither Magnesium?
Magnesium is a chemical element with the atomic number
12, an atomic weight of 24, and the common oxidation
number 12. Magnesium is an alkaline metal and the
eighth most abundant element in the Earth’s crust, where
it constitutes about 2% by mass, and ninth in the Universe.
Magnesium is easily built up in supernova stars by the se-
quential addition of three helium nuclei to carbon. Magne-
sium ion’s high solubility in water helps ensure that it is the
third most abundant element dissolved in seawater. Thus,
magnesium seems ubiquitous and countless products
contain magnesium. My wife swears by her GSR Magne-
sium IQ skis; I can offer no comment in that regard. A
crude facsimile of magnesium is offered in Figure 1.
Magnesium is the second most prevalent intracellular
cation and the fourth most abundant cation in the body.
Magnesium is integral to the function of adenosine tri-
phosphate and plays a role in a host of enzymatic reac-
tions and transport processes, and in the synthesis of
proteins, DNA and RNA. Oddly, magnesium gets relatively
short shrift in terms of physician education. Disorders of
magnesium metabolism made hardly 1.3 pages in my
most recent edition of a commonly used Internal Medi-
cine textbook [1]. The topic did a bit better in a textbook
devoted solely to fluid and electrolyte metabolism [2]. The
lay public seems a bit more aware. They generally know that
grains, nuts, milk and green leafy vegetables provide mag-
nesium. They are convinced that magnesium is ‘good for
you’. They know for instance that magnesium cures leg
cramps, although the Cochrane Review folks are less con-
vinced. Many people travel to the Dead Sea to get at it;
presumably they absorb it through the skin, who knows?
One of my favourite clinical teachers, Robert Whang,
scoured intensive care units of our hospitals checking the
patients for magnesium deficiency [3]. In a survey of 1033
serum specimens for electrolyte analysis in an acute-care
hospital, he and an associate found that 53% of the pa-
tients had magnesium levels <0.74 mmol/L, while the or-
dering physicians suspected and ordered magnesium
levels specifically in only 10% of patients. Whang and
Ryder concluded that in many patients, magnesium dis-
turbances were not being detected. They recommended
that routine magnesium measurements should be per-
formed in acutely ill patients when electrolyte disturbances
are suspected [4]. Whang was also interested in the rela-
tionship between magnesium and potassium, particularly
intracellular potassium stores. He and an associate drew
attention to the close interrelationship of magnesium, cal-
cium and intracellular potassium. Clinically, magnesium
deficiency is associated with hypocalcaemia, kaliuresis
and hypokalaemia [5]. Decreased Na-K pump density in
cells decreases ATPase activity; and increased cell mem-
brane permeability related to intracellular potassium de-
pletion are mechanisms that they implicate. Since the
kidneys eliminate magnesium, nephrologists would be ex-
pected to know the most about it. The daily intake of mag-
nesium is ~15 mmol of which approximately one third is
absorbed. The circulating pool amounts to ~7.6 mmol and
is in equilibrium with bone magnesium which is ~530 mmol,
muscle magnesium ~270 mmol, other intracellular places
~190 mmol and erythrocytes ~5 mmol. Of the 5 mmol ab-
sorbed, the kidneys excrete 4 mmol and the rest is elimina-
ted by other means. Robert Whang recognized that serum
measurements, while practicable, were not adequate re-
flections of total body stores and took to measuring
magnesium in mononuclear cells. Erythrocytes are ap-
parently inexact reflectors.
Dialysis patients cannot eliminate magnesium via their
kidneys. The dialysate is adjusted accordingly. Such patients
should be prime candidates of interest regarding magne-
sium metabolism. The other cations have done pretty well,
sodium in terms of volume regulation, potassium in terms
of Nernst-Equation problems (like sudden cardiac death)
and calcium in terms of bone disease. The relationship
between serum magnesium concentrations and renal
function is based on a (seminal) study from 40 years
ago; the values were all over the map and were typically
high. However, the authors did not report that the patients
developed any symptoms related to their magnesium lev-
els [6]. I was taught that magnesium, similar to potassium,
was ‘dangerous’ in dialysis patients and could cause similar
symptoms to hyperkalaemia. Forty years ago, before the
advent of histamine receptor-2 blockers and proton-pump
inhibitors, gastric disorders were treated with antacids and
the favourite was Maalox. The compound contains alu-
minum hydroxide and magnesium hydroxide to neutralize
or reduce stomach acid. Dire were the consequences and
limited was the future for any nephrology fellow who did
not eliminate Maalox from the treatment venue of any
renal patient! Getting fired in those days was relatively
Fig. 1. The magnesium atom with its protons, neutrons, and electrons is
displayed.
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easy. Does hypermagnesaemia kill people? Perusal of the
literature identified possible victims of acute poisoning,
like ingesting water from the Dead Sea, but required values
in excess of 10 mmol/L. Was that entire hullabaloo justi-
fied? I am no longer certain, because magnesium-contain-
ing phosphate binders could provide an attractive answer
for multiple problems.
New exciting discoveries on the relevance of magnesium
are being regularly reported. The magnesium ion is essen-
tial for all life as a cofactor for ATP, polyphosphates such as
DNA and RNA and metabolic enzymes. Recently, Li et al [7]
identified mutations in the magnesium transporter gene,
MAGT1, in a novel X-linked human immunodeficiency syn-
drome characterized by CD4 lymphopenia, severe chronic
viral infections and defective T-lymphocyte activation.
They demonstrated that a rapid transient magnesium in-
flux is induced by antigen-receptor stimulation in normal T
cells and by growth-factor stimulation in non-lymphoid
cells. MAGT1 deficiency abrogated the magnesium influx,
which impaired responses to antigen receptor engagement,
including defective activation of phospholipase Cc1 and a
markedly impaired calcium influx into T cells. These obser-
vations reveal a novel role for magnesium as an intracellular
second messenger that couples cell-surface receptor acti-
vation to intracellular effectors. The findings identify MAGT1
as a possible target for novel therapies in immune disorders.
More importantly, the findings usher in a specific role for
magnesium trafficking in regulating immunity.
With this compendium, we would like to provide general
nephrologists with a practicable overview of magnesium
metabolism and what it means for their patients. We have
gathered a group of basic scientists and experienced clini-
cians to deal with the issues involved. Importantly, substan-
tial new knowledge has been accrued about magnesium
and new avenues have been opened for patients. These
avenues will demand rigorous, well-designed clinical stud-
ies, but our patients would expect no less. Willi Jahnen-
Dechent and Markus Ketteler introduce us to magnesium
and do not spare us from some important inorganic infor-
mation about the element. Jeroen de Baaij, Joost Hoen-
derop and Rene´ Bindels discuss the amazing advances in
molecular genetics concerning magnesium metabolism,
including the channels responsible for magnesium trans-
port. Helmut Geiger and Christoph Wanner discuss mag-
nesium in the general population. Does magnesium
metabolism contribute to arterial hypertension? My first
brush with this topic was based on two landmark papers
from the early 1980’s [6,8]. These papers implicated mag-
nesium deficiency in hypertension and blood vessel rarefi-
cation; what has happened since then? What do we know
about magnesium in chronic kidney disease before dialysis
and afterwards? John Cunningham, Mariano Rodrı´guez,
and Piergiorgio Messa present what is known about this
issue. Ziad Massy and Tilman Dru¨eke tackle the issue of
magnesium and outcomes in CKD patients, focusing on
vascular calcification. The exciting tenor of the discussions
could be that magnesium interferes with vascular calcifi-
cation and since most dialysis patients die from vascular
disease, such a result would be of amazing significance.
On the downside, there is nagging doubt (ignorance)
about the effects of magnesium on chronic bone disease.
Here is where most of the magnesium in the body ‘is at’.
Could additional magnesium access influence bone disease
and how could we find out?
Alastair Hutchison and Martin Wilkie review the use of
magnesium as a drug in chronic kidney disease patients.
All of us who prescribed Maalox knew that the com-
pound was a great phosphate binder. Could a calcium
acetate/magnesium carbonate binder solve some prob-
lems that we have with the other products? A randomized
controlled trial has been performed to test the efficacy in
terms of phosphate and parathyroid hormone control. And
with this trial, we come full circle.
There are numerous missing variables and complex clin-
ical research issues. Do phosphate binders prolong life of
dialysis patients? I would not insist that this hypothesis
be tested. Evidently, they do reduce fracture risk. Calcium-
containing phosphate binders have been implicated in vas-
cular calcifications. Could a magnesium-containing com-
pound circumvent or even alleviate this problem? Would
magnesium-containing phosphate binders make bone dis-
ease better or worse? What would be the interaction be-
tween a magnesium-containing phosphate binder and the
calcium-sensing receptor? Magnesium has three stable
isotopes: 24Mg, 25Mg and 26Mg. About 79% of Mg is 24Mg.
Stable isotopes provide a non-radioactive opportunity for
great clinical research. I see an opportunity for important
clinical research on not only dialysis-related issues, but also
regarding magnesium metabolism as a whole entity. Let us
go for it, whole-heartedly. And, in the meantime, perhaps
we could figure out what really causes those obnoxious leg
cramps!
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